Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Will Alkermes Data Package Support ALKS 5461 Approval?

Executive Summary

Alkermes revealed successful completion of its third Phase III trial for the depression drug ALKS 5461 as well as a risky plan to seek FDA approval based on two negative and one positive late-stage study.


Related Content

Durability Still In Question For Acadia's Nuplazid In Alzheimer’s Psychosis
No More Sarepta-Like Development, FDA Officials Say
Keeping Track: Approvals For Nuplazid, Cabometyx, Bevespi And More; Digital Aripiprazole Tablet Needs More Study
FDA's Thinking On New Psychiatric Endpoints: What Does Brintellix CRL Portend For Nuplazid?
FDA Reverses Position On Fabre-Kramer's Gepirone, Clearing Way For Approval
COMMENT: Alkermes Needs New Strategy In Wake Of Trial Failures
An Iffy Future For Alkermes After Failed Trials
Alkermes Strategy After Antidepressant Failures Doubted By Wall Street
Do Negative Trials Count More Than Successful Ones?
Keeping Track: Rexulti, Iressa Approved; Takeda Submits Oral Myeloma Drug Ixazomib


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts